Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial
Journal of Clinical Oncology · 2026
DOI: 10.1200/jco-25-02465 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Frank A Vicini und 24 weiteren Autor:innen. Beteiligte Einrichtung: Michigan Healthcare Professionals Farmington, Farmington Hills, MI. Hauptthemen laut MEDLINE: Breast Neoplasms, Mastectomy, Segmental, Radiotherapy, Conformal, Radiotherapy, Intensity-Modulated. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE For patients with breast cancer undergoing breast conservation, escalating the dose (boost) of radiation to the lumpectomy cavity after whole-breast irradiation (WBI) reduces ipsilateral breast recurrence (IBR) but extends treatment duration. This phase III trial investigated whether boost delivery during WBI versus after WBI provides noninferior IBR and preserves cosmetic appearance. METHODS NRG/RTOG 1005 randomly assigned patients at higher risk for IBR after lumpectomy and axillary surgery to either a sequential boost of 12 Gy in six fractions(F) or 14 Gy in 7F after WBI of 50 Gy in 25F or 42.7 Gy in 16F (sequential arm) or a concurrent boost of 8 Gy in 15F of 0.53 Gy per day with WBI of 40 Gy in 15F (concurrent arm) using 3-dimensional conformal radiation therapy (RT) or intensity-modulated RT. Based on 1.59% 5-year IBR for the sequential arm, defining the noninferiority margin as a hazard ratio upper limit on the 90% CI of 2.12, 2,312 patients provide 80% power for noninferiority of IBR as first recurrence for the concurrent arm. Secondary end points included disease-free survival and overall survival, adverse events (AEs), and cosmetic outcomes. RESULTS Between May 24, 2011, and June 20, 2014, 2,354 patients were randomly assigned, with 2,255 eligible for analysis (sequential arm, n = 1,118; concurrent arm, n = 1,137). With median follow-up of 7.3 years, there were 56 IBR events; 5- and 7-year IBR were 2.1% and 2.2% on the sequential arm and 1.9% and 2.6% on the concurrent arm, respectively. The noninferiority criterion was met: HR (90% CI): 1.31 (0.84 to 2.04), P = .037. No differences were observed in AEs, cosmetic outcomes, or survival between arms. CONCLUSION Concurrent boost during WBI results in noninferior IBR compared with sequential boost without worsening toxicity or cosmetic outcomes and reduces overall treatment time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Michigan Healthcare Professionals Farmington, Farmington Hills, MI.
- NRG Oncology Statistics and Data Management Center, Philadelphia, PA.
- University of Pennsylvania/Abramson Cancer Center, Philadelphia, PA.
- Virginia Commonwealth University/Massey Cancer Center, Richmond, VA.
- Mount Sinai Hospital, New York, NY.
- University of Maryland/Greenebaum Cancer Center, Baltimore, MD.
ORCID-Profile: Frank A Vicini, X Allen Li, Wendy A Woodward, Richard J Bleicher, Alphonse Taghian, Janice Lyons, Samantha A Seaward, Andrew C Hoover, Bethany M Anderson, Francisco E Perera, Sachin Jhawar, Tarek Hijal, Benjamin Movsas, Julia R White
Förderung
- NCI NIH HHS
Zitieren
APA
Vicini, F. A., Winter, K., Freedman, G. M., Arthur, D. W., Rosenstein, B. S., Bentzen, S. M., Li, X. A., Halyard, M. Y., Woodward, W. A., Bleicher, R. J., Taghian, A., Lyons, J., Tomberlin, J. K., Seaward, S. A., Cheston, S. B., Hoover, A. C., Anderson, B. M., Perera, F. E., Poppe, M. M., …, & White, J. R. (2026). Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-02465
Vancouver
Vicini FA, Winter K, Freedman GM, Arthur DW, Rosenstein BS, Bentzen SM, et al. Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial. Journal of Clinical Oncology. 2026. doi:10.1200/jco-25-02465
BibTeX
@article{Vicini2026,
author = {Vicini, Frank A and Winter, Kathryn and Freedman, Gary M and Arthur, Douglas W and Rosenstein, Barry S and Bentzen, Soren M and Li, X Allen and Halyard, Michele Y and Woodward, Wendy A and Bleicher, Richard J and Taghian, Alphonse and Lyons, Janice and Tomberlin, Janice K and Seaward, Samantha A and Cheston, Sally B and Hoover, Andrew C and Anderson, Bethany M and Perera, Francisco E and Poppe, Matthew M and Petersen, Ivy A and Jhawar, Sachin and Hijal, Tarek and Moughan, Jennifer and Movsas, Benjamin and White, Julia R},
title = {Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-25-02465}
}
EUVIMED